Upcoming CTTI Webinar 5/18: Making Registries Into Reusable Platforms for Conducting Clinical Trials

Visit https://www.ctti-clinicaltrials.org/news/upcoming-webinar-making-registries-reusable-platforms-conducting-clinical-trials for more information. Recording of the event will be available about one week after after the presentation.


By using registries as reusable platforms for clinical trials, we can improve the speed and cost of clinical trials and bring new treatments to patients faster.

Join us for a special webinar in which we will unveil new recommendations describing how to design new registries or evaluate and modify existing registries to conduct clinical trials suitable for regulatory purposes.

Title: CTTI Recommendations from the Registry Trials Project
Date: May 18, 2017 12:00–1:00 p.m. ET (GMT-05:00)

ADD TO CALENDAR

Speakers:

  • John Laschinger, MD, Medical Officer, Center for Devices and Radiological Health, U.S. Food and Drug Administration
  • Jules Mitchel, MBA, PhD, president, Target Health Inc.

The webinar will include the following practical, evidence-based strategies:

  • Assess the reliability, relevance, and robustness of registry data
  • Assure patient protections
  • Make modifications needed to accommodate research needs

HHS Publishes Final Revisions to the Common Rule

January 18, 2017 Final rule enhances protections for research participants, modernizes oversight system

Significant changes made in response to public comments

The U.S. Department of Health and Human Services and 15 other federal agencies today issued a final rule to update regulations that safeguard individuals who participate in research. Most provisions in the new rule will go into effect in 2018.

Read the complete press release

Read the final document

New! Understanding and Improving Post-MI Medication Adherence Podcast

The Evidence-to-Practice Podcast Series: Transitions of Care

Understanding and Improving Post-MI Medication Adherence

kristen-newbyKristin Newby, MD, and Jennifer Rymer, MD, discuss reasons behind medication non-adherence and potential ways to lower related readmission rates. Education, insurance, medication cost, and post-discharge follow-up timing are among the issues addressed. They reference several studies that seek greater insights into adherence and non-adherence, including the ARTEMIS multi-center trial of which Duke is a part. They also discuss a promising new interactive teaching tool developed at Duke to help patients understand and manage their medication.

Listen to the podcast

The Case for Coordinated Patient Care Post Discharge Podcast

The Evidence-to-Practice Podcast Series: Transitions of Care

The Case for Coordinated Patient Care Post Discharge

An expert team from the Duke Heart Center and The Fuqua School of Business discuss how data capture and communication can improve the transition of the MI patient from the hospital to home and thereby prevent new complications. They look specifically at how the Duke Health System uses follow-up phone calls to address issues such as medication reconciliation.

Presenters

Bradi Granger, PhD, MSN, RN

Joseph Kelly, Administrative Director, Duke Heart Center

Matt Conley, MBA Candidate, The Fuqua School of Business

 

What is the Optimal Antiplatelet Therapy Duration After Acute MI? Podcast

The Evidence-to-Practice Podcast Series: Transitions of Care

What is the Optimal Antiplatelet Therapy Duration After Acute MI?

Tracy Wang, MD, MHS, MSc, and Jeffrey Washam, PharmD, discuss clinical data regarding antiplatelet therapy for acute post-myocardial infarction patients, including questions about medication adherence, triple therapy, and aspirin dosage. They also address a report published in the most recent issue of the Journal of the American College of CardiologyThe study compares the incidence of death, hemorrhage, MI, stent thrombosis, and adverse cardiac events when dual antiplatelet therapy is combined with drug-eluting stents and as part of the long-term therapy of stable post-MI patients.

Listen Now

Anticoagulants vs. Filter Devices for Left Atrial Appendage Closure Podcast

New! Interventional Cardiology Podcast Series: Anticoagulants vs. Filter Devices for Left Atrial Appendage Closure

Which option is best for managing stroke prevention in patients at risk for bleeding?

Jonathan P. Piccini, MD, MHS and Sean D. Pokorney, MD, MBA discuss the case of a 68-year-old man with a history of diabetes, hypertension, peripheral artery disease, and gastrointestinal bleeds. They refer to the PROTECT AF Trial and the PREVAIL Trial to assess left atrial appendage closure with the FDA-approved Watchman filter device as an alternative to warfarin therapy.

Listen Now

 

The Case for Drug-eluting vs Bare-metal Stents Podcast

Interventional Cardiology Podcast Series: The Case for Drug-Eluting vs Bare-Metal Stents in Coronary Artery Disease Patients

Free registration required to listen to the podcast.

sunil-raoIs a drug-eluting stent or a bare-metal stent the safest option for patients requiring percutaneous coronary intervention (PCI), including those with a bleeding history or a risk for bleeding? What are the revascularization and stent thrombosis risks?

Sunil Rao, MD, and Ajar Kochar, MD, discuss the case of a 62-year-old patient with a history of hypertension, tobacco use, and recent diverticular-related bleeding. As part of their discussion, they refer to the NORSTENT study published in the most recent issue of The New England Journal of Medicine. The article, “Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease,” describes a randomized clinical trial involving more than 9,000 patients who underwent PCI with the implantation of either drug-eluting stents or bare-metal stents.

This is the sixth of eight monthly Interventional Cardiology podcasts from DCRI Education, whose mission it is to accelerate the adoption of research to practice.